Analisi facoltativa del prodotto
Con il tuo consenso utilizziamo analisi limitate e rispettose della privacy per capire quali percorsi di ricerca funzionano. Non usiamo tracker pubblicitari né registrazioni delle sessioni. Puoi modificare questa scelta nelle Preferenze. Leggi la Informativa sulla privacy.
Moderna Inc.'s published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $21.1B | |
|---|---|---|
| Revenue (ttm) | 2.2B | |
| Net income (ttm) | -3.2B | |
| EPS (ttm) | -$8.01 | |
| Shares out | 399.2M | |
| Volume | 10,987,308 | |
| Beta | 1.09 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $17.74B | $18.88B | $6.75B | $3.20B | $1.92B | -42.6% |
| Gross profit | $15.12B | $13.46B | $2.06B | $1.74B | $1.05B | -48.6% |
| Operating income | $13.30B | $9.42B | $-4.24B | $-3.58B | $-2.76B | — |
| Net income | $12.20B | $8.36B | $-4.71B | $-3.56B | $-2.82B | — |
| EPS (diluted) | $28.29 | $20.12 | $-12.33 | $-9.28 | — | — |
| EBITDA | $13.53B | $9.77B | $-3.62B | $-3.39B | $-2.54B | — |
| R&D | $1.99B | $3.30B | $4.85B | $4.54B | $3.13B | +12.0% |
| SG&A | $567.0M | $1.13B | $1.55B | $1.17B | $1.02B | +15.8% |
Recent company headlines from major financial publishers.
The mRNA platform's speed and adaptability result in best-in-class efficacy for multiple latent virus and oncology targets. MRNA establishes a broad, highly profitable commercial portfolio, driving revenues back toward $10B+ with 70%+ gross margins and substantial operating leverage.
Moderna undergoes a high-risk transition, absorbing multi-billion dollar operating losses to sustain its $3.1B R&D engine. The validated mRNA platform produces sufficient new blockbusters to return to revenue growth and reach steady-state profitability by the end of the decade.
| Ke ↓ / g → | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |
|---|---|---|---|---|---|
| 7.5% | $68.8 | $75.7 | $84.0 | $94.5 | $102 |
| 8.5% | $58.3 | $63.1 | $68.8 | $75.7 | $84.0 |
| 9.5% | $50.6 | $54.2 | $58.3 | $63.1 | $68.8 |
| 10.5% | $44.6 | $47.4 | $50.6 | $54.2 | $58.3 |
| 11.5% | $40.0 | $42.2 | $44.6 | $47.4 | $50.6 |
Upcoming earnings date and setup when available.
Il rating riportato dall'edizione di ricerca pubblicata ogni mese. Un rating confronta il prezzo alla data dell'analisi con il valore equo; non indica se la valutazione si è rivelata corretta.
| Anno | gen | feb | mar | apr | mag | giu | lug | ago | set | ott | nov | dic |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
